Recent cancellation of federally funded grants results in significant changes for the university's global health activities ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...
An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
The cancellation of USAID contracts has threatened critical global health research. Plus, new guidance to prevent HIV in ...
Ethiopia with its over 125 million people had been the biggest beneficiary of U.S. aid in sub-Saharan Africa, receiving $1.8 ...
During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...
Unlike President Trump's picks to lead other health agencies who established their conservative bona fides during the ...
A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...
Primarily a grantmaking agency with an $8 billion budget, SAMHSA channels funds and training that the federal government ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback